"We can also confirm that there was a brief trial pause in July while a safety review took place after one volunteer was confirmed to have an undiagnosed case of multiple sclerosis, which the independent panel concluded was unrelated to the vaccine", a company spokesperson said.
This story was first published on CNN.com, "AstraZeneca's Oxford vaccine trial to resume, the university says".
"We are delighted to have dosed the first subjects in this trial with Serum Institute of India, the world's largest vaccine manufacturer by number of doses produced, and to be advancing this COVID-19 vaccine candidate into clinical trials", said Sumi Biswas, chief executive officer and co-founder of SpyBiotech.
AstraZeneca announced on Wednesday it had "voluntarily paused" its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness. They are not intended and should not be thought to represent official ideas, attitudes, or policies of any agency or institution. The postponement of the clinical trial also puts into question the request of some of the pharma companies for full indemnification from any risks from their vaccines by purchasing countries.
The first delivery of a COVID-19 vaccine could be expected in Malta in December, despite a pause in clinical trials, virologist Chris Barbara said.
Charlotte Summers, lecturer in intensive care medicine at Cambridge University, welcomed the resumption of the Oxford trial and said the researchers had shown their commitment "to putting safety at the heart of their development program".
Donny van de Beek claims Steven Bergwijn texted him about Tottenham
He can play deeper in midfield and alternate with Paul Pogba, Scott McTominay and Fred. But they have failed to acquire the 23-year-old midfielder's abilities.
It said that globally some 18,000 people have received the vaccine as part of the trial.
Chinese state-owned bio-pharm company Sinopharm, through its China National Biotec Group (CNBG) unit, has two inactivated vaccines.
The Pfizer and BioNTech study is likely to be among the first in the U.S. to report efficacy data from a Phase 3 trial.
Recently, the vaccine progressed to Phase 3 testing, which meant it was able to be trialled on large numbers of patients across different geographies.
Although many of these experimental vaccine candidates are in the phase-3 trials, "there is no guarantee that any of these six will give us the answer", as Michael Ryan, executive director of the WHO Health Emergencies Program said in August.